Investigation in the cannabigerol derivative VCE-003.2 as a disease- modifying agent in a mouse model of experimental synucleinopathy

Here we explore the striatum transcriptomic effects of alpha-synuclein administration in mice as model of Parkinson´s disease. Moreover, we also explore the neuroprotective effect of cannabonoid-based druga (VCE-003.2) as a potential neuroportective agent in Parkinson´s disease